Malaria has been prevalent long enough for it to be able to make it to a Bollywood song. But we finally have a breakthrough to be able to prevent this infectious parasitic disease, that has caused lakhs and lakhs of deaths worldwide, year after year.

On 6 October, the World Health Organisation recommended the world's first malaria vaccine — Mosquirix that has been developed by British pharmaceutical GlaxoSmithKline in 1987, for malaria prevention in children living in regions with moderate to high transmission of this disease.

Children under five, it has been found out, are the most susceptible to malaria. In 2019, they accounted for 67 percent (274 000) of all malaria deaths worldwide.


The WHO's recommendation for administering Mosquirix to children is based on the data of an ongoing pilot programme in Ghana, Kenya and Malawi that has been able to provide more than 2.3 million doses to over 8,00,000 children, since 2019.


The efficacy of the vaccine has been proven to be around 40 percent so basically it can prevent four out of ten cases of malaria. Sure, that's not foolproof but experts have a reason to believe that it is a remarkable development. 

The pilot drive found out that the vaccine is safe, it's cost effective, it improves health and can saves lives with good and equitable coverage that can be assured through routine immunization.

And, most importantly, this vaccine was found to be able to prevent three out ten cases of severe malaria.


But how does Mosquirix work? Why did it take so long to develop this vaccine? What will be the impact of scientific development in developing countries in Africa and also India where malaria infections are prevalent?

Tune in!

Host and Producer: Shorbori PurkayasthaGuest: Dr Ambarish Dutta, Associate Professor of epidemiology at the Indian Institute of Public Health, BhubaneswarEditor: Vaishali Sood
Music: Big Bang Fuzz

References: WHO Approves World’s First Malaria Vaccine: All You Need To Know
Listen to The Big Story podcast on:
Apple: https://apple.co/2AYdLIlSaavn: http://bit.ly/2oix78CGoogle Podcasts: http://bit.ly/2ntMV7SSpotify: https://spoti.fi/2IyLAUQDeezer: http://bit.ly/2Vrf5NgCastbox: http://bit.ly/2VqZ9ur

<div>Malaria has been prevalent long enough for it to be able to make it to a Bollywood song. But we finally have a breakthrough to be able to prevent this infectious parasitic disease, that has caused lakhs and lakhs of deaths worldwide, year after year.<br>
<br>

</div>
<div>On 6 October, the World Health Organisation recommended the world's first malaria vaccine — Mosquirix that has been developed by British pharmaceutical GlaxoSmithKline in 1987, for malaria prevention in children living in regions with moderate to high transmission of this disease.<br>
<br>

</div>
<div>Children under five, it has been found out, are the most susceptible to malaria. In 2019, they accounted for 67 percent (274 000) of all malaria deaths worldwide.<br>
<br>
The WHO's recommendation for administering Mosquirix to children is based on the data of an ongoing pilot programme in Ghana, Kenya and Malawi that has been able to provide more than 2.3 million doses to over 8,00,000 children, since 2019.<br>
<br>
The efficacy of the vaccine has been proven to be around 40 percent so basically it can prevent four out of ten cases of malaria. Sure, that's not foolproof but experts have a reason to believe that it is a remarkable development. <br>
<br>

</div>
<div>The pilot drive found out that the vaccine is safe, it's cost effective, it improves health and can saves lives with good and equitable coverage that can be assured through routine immunization.<br>
<br>

</div>
<div>And, most importantly, this vaccine was found to be able to prevent three out ten cases of severe malaria.<br>
<br>
But how does Mosquirix work? Why did it take so long to develop this vaccine? What will be the impact of scientific development in developing countries in Africa and also India where malaria infections are prevalent?<br>
<br>

</div>
<div>Tune in!<br>
<br>
<strong>Host and Producer: </strong>Shorbori Purkayastha</div>
<div>
<strong>Guest: </strong>Dr Ambarish Dutta, Associate Professor of epidemiology at the Indian Institute of Public Health, Bhubaneswar</div>
<div>
<strong>Editor:</strong> Vaishali Sood</div>
<div><br>
</div>
<div>
<strong>Music:</strong> Big Bang Fuzz<br>
<br>
<strong>References: </strong>
</div>
<h1><a href="https://fit.thequint.com/health-news/who-approves-worlds-first-malaria-vaccine">WHO Approves World’s First Malaria Vaccine: All You Need To Know</a></h1>
<div><br>
</div>
<div><strong>Listen to The Big Story podcast on:</strong></div>
<div><br>
</div>
<div>Apple: <a href="https://www.youtube.com/redirect?q=https%3A%2F%2Fapple.co%2F2AYdLIl&amp;redir_token=G9sQMbbppKv-LEFD29gDyTmPMzt8MTU3MTM4MDU5NkAxNTcxMjk0MTk2&amp;v=xkpX1V6aUFo&amp;event=video_description">https://apple.co/2AYdLIl</a>
</div>
<div>Saavn: <a href="https://www.youtube.com/redirect?q=http%3A%2F%2Fbit.ly%2F2oix78C&amp;redir_token=G9sQMbbppKv-LEFD29gDyTmPMzt8MTU3MTM4MDU5NkAxNTcxMjk0MTk2&amp;v=xkpX1V6aUFo&amp;event=video_description">http://bit.ly/2oix78C</a>
</div>
<div>Google Podcasts: <a href="https://www.youtube.com/redirect?q=http%3A%2F%2Fbit.ly%2F2ntMV7S&amp;redir_token=G9sQMbbppKv-LEFD29gDyTmPMzt8MTU3MTM4MDU5NkAxNTcxMjk0MTk2&amp;v=xkpX1V6aUFo&amp;event=video_description">http://bit.ly/2ntMV7S</a>
</div>
<div>Spotify: <a href="https://www.youtube.com/redirect?q=https%3A%2F%2Fspoti.fi%2F2IyLAUQ&amp;redir_token=G9sQMbbppKv-LEFD29gDyTmPMzt8MTU3MTM4MDU5NkAxNTcxMjk0MTk2&amp;v=xkpX1V6aUFo&amp;event=video_description">https://spoti.fi/2IyLAUQ</a>
</div>
<div>Deezer: <a href="https://www.youtube.com/redirect?q=http%3A%2F%2Fbit.ly%2F2Vrf5Ng&amp;redir_token=G9sQMbbppKv-LEFD29gDyTmPMzt8MTU3MTM4MDU5NkAxNTcxMjk0MTk2&amp;v=xkpX1V6aUFo&amp;event=video_description">http://bit.ly/2Vrf5Ng</a>
</div>
<div>Castbox: <a href="http://bit.ly/2VqZ9ur">http://bit.ly/2VqZ9ur</a>
</div>

The Big Story is back with a second season!

The news culture of our times is noisy, crowded, and honestly so confusing. This is why we are coming every fortnight on your podcast platforms to help you make sense of the new and now. 

With two new hosts, Anjali and Prateek, the second season of The Big Story will feature longer and well-rounded discussions with experts across science, culture, technology, politics, and more. Tune in on your preferred podcast platform!   



Millions of listeners seek out Bingepods (Ideabrew Studios Network content) every day. Get in touch with us to advertise, join the network or click listen to  enjoy content by some of India's top audio creators.
studio@ideabrews.com

Android | Apple

<p>The Big Story is back with a second season!</p>
<p>The news culture of our times is noisy, crowded, and honestly so confusing. This is why we are coming every fortnight on your podcast platforms to help you make sense of the new and now. <br aria-hidden="true"><br aria-hidden="true">With two new hosts, Anjali and Prateek, the second season of The Big Story will feature longer and well-rounded discussions with experts across science, culture, technology, politics, and more. Tune in on your preferred podcast platform!   </p>
<p> </p>
<p><em>Millions of listeners seek out <a href="https://bingepods.com/">Bingepods</a> (Ideabrew Studios Network content) every day. Get in touch with us to advertise, join the network or click listen to  enjoy content by some of India's top audio creators.</em><br><em><a href="mailto:studio@ideabrews.com">studio@ideabrews.com</a></em></p>
<p><a href="https://play.google.com/store/apps/details?id=com.bingepods.app">Android</a> | <a href="https://apps.apple.com/us/app/bingepods/id1637568609">Apple</a></p>

Advertisement